Cannara Biotech Inc.

    Cannara Biotech Inc.

    TTSXV:LOVE
    - -
    CAD
    - -
    - -
    17.46P/E
    Cannara Biotech Inc.
    TSXV:LOVE
    (TSX Venture Exchange)

    Recent

    price

    - -

    P/E

    ratio

    17.46

    div

    yld

    - -

    ROIC.AI

    2018
    2019
    2020
    2021
    2022
    2023
    2024
    2025
    TTM
    CAD
    - -
    0.03
    0.04
    0.22
    0.41
    0.64
    0.91
    1.18
    1.2
    Revenue per Share
    -0.03
    -0.2
    -0.17
    -0.02
    0.03
    0.08
    0.07
    0.14
    0.11
    Basic EPS, GAAP
    -0.23
    -0.5
    -0.26
    -0.43
    -0.25
    -0.04
    0.04
    0.15
    0.17
    Free Cash Flow per Basic Share
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    Dividend per Share
    0.2
    0.66
    0.44
    0.71
    0.65
    0.78
    0.84
    0.99
    1.14
    Book Value per Share
    0.21
    0.81
    0.54
    0.84
    0.76
    0.89
    0.98
    1.12
    1.28
    Tangible Book Value per Share
    69
    61
    71
    77
    88
    89
    90
    91
    94
    Basic Weighted Avg Shares
    - -
    2
    3
    17
    36
    57
    82
    107
    113
    Sales/Revenue/Turnover
    - -
    -487.52
    -467.66
    1.76
    13.88
    20.99
    9.84
    20.31
    15.74
    Operating Margin (%)
    - -
    1
    3
    3
    4
    5
    6
    7
    6
    Depreciation Expense
    -2
    -12
    -12
    -2
    2
    7
    6
    13
    10
    Net Income, GAAP
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    27.74
    33.15
    Effective Tax Rate (%)
    - -
    -587.28
    -489.35
    -8.98
    6.43
    12.13
    7.88
    12.2
    9
    Profit Margin (%)
    12
    23
    7
    12
    29
    31
    40
    48
    61
    Working Capital
    13
    13
    12
    20
    46
    40
    39
    28
    25
    LT Debt
    15
    50
    38
    64
    67
    80
    88
    102
    120
    Total Equity
    - -
    - -
    - -
    - -
    4.96
    9.73
    - -
    10.58
    7.64
    Return on Invested Capital (%)
    - -
    - -
    - -
    - -
    5.63
    10.4
    - -
    12.37
    9
    Return on Capital (%)
    - -
    -45.41
    -34.78
    -3.56
    4.13
    10.98
    8.88
    15.8
    10.99
    Return on Common Equity (%)

    Capital Structure

    CAD

    •

    in mil. unless spec.
    Aug'25
    Nov'26
    Feb'26
    ST Debt
    13
    9
    9
    LT Borrowings
    28
    26
    25
    LT Finance Leases
    - -
    - -
    - -
    Preferred Equity and Hybrid Capital
    - -
    - -
    - -
    Shares Outstanding
    91
    95
    96
    Market Capitalization
    163
    155
    177

    Working Capital

    CAD

    •

    in mil. unless spec.
    Aug'25
    Nov'26
    Feb'26
    Total Current Assets
    82
    85
    91
    Cash, Cash Equivalents & STI
    14
    17
    22
    Accounts Receivable, Net
    14
    15
    12
    Inventories
    51
    52
    54
    Total Current Liabilities
    34
    31
    30
    Payables & Accruals
    21
    22
    21
    ST Debt
    13
    9
    9
    Deferred Revenue
    - -
    - -
    - -

    Growth Rates

    CAD

    •

    in mil. unless spec.

    (avg. rate of change)

    10 years
    5 years
    1 year
    Total Equity
    - -
    23.44%
    16.22%
    Free Cash Flow
    - -
    21.04%
    324.86%
    Net Income, GAAP
    - -
    -8.31%
    103.09%
    Sales/Revenue/Turnover
    - -
    162.3%
    31.14%
    Total Cash Common Dividend
    - -
    - -
    - -

    Quarterly Revenue

    CAD

    •

    in mil. unless spec.

    Year

    Q1
    Q2
    Q3
    Q4
    FY
    2024
    19
    20
    20
    23
    82
    2025
    25
    27
    27
    28
    107
    2026
    30
    27
    - -
    - -
    - -

    Quarterly Earnings Per Share

    CAD

    •

    in mil. unless spec.

    Year

    Q1
    Q2
    Q3
    Q4
    FY
    2024
    0.02
    -0.04
    0.02
    - -
    0.07
    2025
    0.03
    0.04
    0.05
    - -
    0.14
    2026
    0.01
    0.02
    - -
    - -
    - -

    Quarterly Dividends Per Share

    CAD

    •

    in mil. unless spec.

    Year

    Q1
    Q2
    Q3
    Q4
    FY
    2024
    - -
    - -
    - -
    - -
    - -
    2025
    - -
    - -
    - -
    - -
    - -
    2026
    - -
    - -
    - -
    - -
    - -
    Similar Companies
    Business